Hydroxyzine and Alrex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hydroxyzine (hydroxyzine hydrochloride) and Alrex (loteprednol etabonate). Common drug interactions include ocular hyperaemia among females and benign prostatic hyperplasia among males.

The phase IV clinical study analyzes what interactions people have when they take Hydroxyzine and Alrex. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Hydroxyzine?

Hydroxyzine has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 54,069 Hydroxyzine users. Check the latest studies of Hydroxyzine.

What is Alrex?

Alrex has active ingredients of loteprednol etabonate. eHealthMe is studying from 663 Alrex users. Check the latest studies of Alrex.



On Jul, 04, 2026

13 people who take Hydroxyzine and Alrex together, and have interactions are studied.

Hydroxyzine and Alrex drug interactions.

What are the common drug interactions of Hydroxyzine and Alrex, by gender? *:

female:

  1. Ocular hyperaemia (an abnormally large amount of blood in eye)
  2. Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer)
  3. Discomfort
  4. Endophthalmitis (inflammation of the internal coats of the eye)
  5. Erythema (redness of the skin)
  6. Eye infection
  7. Pain
  8. Chronic kidney disease
  9. Colitis microscopic (inflammation of colon with diarrhoea and abdominal cramps)
  10. Fatigue (feeling of tiredness)

male:

  1. Benign prostatic hyperplasia (benign enlargement of the prostate)
  2. Hypertension (high blood pressure)
  3. Obesity (having too much body fat)
  4. Therapeutic response unexpected
  5. Chronic kidney disease
  6. Renal failure (kidney dysfunction)
  7. Weight decreased

What are the common drug interactions of Hydroxyzine and Alrex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Benign prostatic hyperplasia (benign enlargement of the prostate)
  2. Discomfort
  3. Endophthalmitis (inflammation of the internal coats of the eye)
  4. Erythema (redness of the skin)
  5. Eye infection
  6. Eye irritation
  7. Hypertension (high blood pressure)
  8. Obesity (having too much body fat)
  9. Pain
  10. Therapeutic response unexpected

60+:

  1. Arthralgia (joint pain)
  2. Eye irritation
  3. Eye pruritus (eye itching)
  4. Ocular hyperaemia (an abnormally large amount of blood in eye)
  5. Chronic kidney disease
  6. Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer)
  7. Renal failure (kidney dysfunction)
  8. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  9. Nephrogenic anaemia (anaemia due to kidney disease)
  10. Viral infection

What are the existing conditions these people have? *

  1. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 23.08%
  2. Seasonal Allergy (allergic condition due to certain season): 3 people, 23.08%
  3. Depression: 3 people, 23.08%
  4. Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 15.38%
  5. Temporomandibular Joint Syndrome (pain at the temporomandibular joint due to various causes of increased muscle tension and spasm. it is believed that syndrome is a physical manifestation of psychological stress): 2 people, 15.38%
  6. Migraine (headache): 2 people, 15.38%
  7. Essential Tremor: 2 people, 15.38%
  8. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 15.38%
  9. Immunodeficiency Common Variable: 2 people, 15.38%
  10. Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Hydroxyzine and Alrex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Hydroxyzine and Alrex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Hydroxyzine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Alrex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Hydroxyzine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Alrex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on hydroxyzine hydrochloride and loteprednol etabonate (the active ingredients of Hydroxyzine and Alrex, respectively), and Hydroxyzine and Alrex (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: